Results 61 to 70 of about 146,300 (194)
Background Scleral buckling has been the standard for rhegmatogenous retinal detachment repair in young patients given the typical lack of posterior vitreous detachment, phakic status, and lower risk of proliferative vitreoretinopathy. In older patients,
Venkatkrish M. Kasetty +7 more
doaj +1 more source
This study developed and validated a machine learning‐based prognostic model for predicting long‐term visual outcomes after pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy. ABSTRACT Introduction This study aims to develop a machine‐learning‐based risk prediction model for a long‐term visual prognosis in patients with ...
Xiaolu Wang +7 more
wiley +1 more source
We experienced a rare case of lens-induced uveitis (LIU) with severe proliferative vitreoretinopathy (PVR) diagnosed upon finding lens nuclear material encapsulated by intravitreal proliferative tissue.
Saki Inoue +4 more
doaj +1 more source
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu +7 more
wiley +1 more source
Proliferative vitreoretinopathy: an update on the current and emerging treatment options. [PDF]
Proliferative vitreoretinopathy (PVR) remains the main cause of failure in retinal detachment (RD) surgery and a demanding challenge for vitreoretinal surgeons.
Ferro Desideri, Lorenzo +4 more
core +2 more sources
Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best +5 more
wiley +1 more source
Proliferative vitreoretinopathy: current and emerging treatments
Ama Sadaka,1 Gian Paolo Giuliari2,31Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA; 2Centro de Cirugía Oftalmológica (CECOF), Caracas, Venezuela; 3Department of Ophthalmology, Domingo Luciani ...
Sadaka A, Giuliari GP
doaj
ABSTRACT Objective To systematically review the structural features of secreted frizzled‑related protein 5 (SFRP5) and its dual regulation of canonical/non‑canonical Wnt signaling, analyze its association with metabolic disorders, and specifically explore the role and mechanisms of the SFRP5–lipid metabolism axis in neural and optic nerve development ...
Qianfang Jia +4 more
wiley +1 more source
Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations
Animal models are indispensable for pharmaceutical investigations. However, investigators often have difficulty choosing the appropriate modal for their research.
Eric Nudleman +2 more
core +1 more source
Overview of neurological, ocular, and genetic findings in individuals with bi‐allelic loss‐of‐function (LoF) ESAM variants. All affected subjects (n = 21) exhibited characteristic neurovascular and neurodevelopmental anomalies, while 45% also showed ocular (mainly retinal) involvement.
Mauro Lecca +7 more
wiley +1 more source

